EUVIMEDEUVIMED entdecken
Open Access

Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies

Amanda E Marinoff iD, Kathryn Aaronson, Anurag K Agrawal iD, Benjamin S Braun iD, Carla Golden, Benjamin J Huang, Jennifer Michlitsch, Erica Southworth, Allyson Thrall, Kieuhoa T Vo iD, Elliot Stieglitz iD

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Amanda E Marinoff und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematologic Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, Alex's Lemonade Stand Foundation for Childhood Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Venetoclax is frequently used as salvage treatment in pediatric, adolescent, and young adult (AYA) patients with advanced hematologic malignancies. However, more data are needed from real‐world studies to guide the safe and appropriate use of venetoclax in this population. Procedure We retrospectively reviewed the medical records of all patients diagnosed with hematologic malignancies less than 30 years of age treated with venetoclax outside of clinical trials at the University of California San Francisco Benioff Children's Hospitals from 2016 to 2022.

Results

We identified 13 patients (acute myeloid leukemia , n = 8; B‐acute lymphoblastic leukemia, n = 3; myelodysplastic syndrome, n = 2) aged 4 months to 27 years. A median of 3 prior lines of therapy weregiven (range 0–5). All patients received venetoclax in combination with either a hypomethylating agent or conventional chemotherapy. Three (23%) patients achieved complete remission (CR); two (15%) achieved partial remission (PR); 3 (23%) had stable disease (SD), and five (42%) had progressive disease. Median survival and time to progression from venetoclax initiation was 9 months (range 2.5–52 months) and 3 months (range 2 weeks to 7.5 months), respectively. Six patients (46%) developed grade 3 or higher infections while receiving venetoclax, including bacteremia due to atypical organisms, invasive pulmonary infections with Aspergillus, cytomegalovirus (CMV) viremia, skin infections, and encephalitis with bacterial brain abscesses.

Conclusions

Venetoclax in combination with hypomethylating agents or cytotoxic chemotherapy was effective in a subset of pediatric/AYA patients with advanced hematologic malignancies, but multiple severe infections were observed, particularly among patients who received venetoclax in combination with chemotherapy. Prospective studies will be required to determine the optimal dose and duration of venetoclax in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematologic NeoplasmsAdolescentYoung AdultHumansChildAdultRetrospective StudiesProspective StudiesBridged Bicyclo Compounds, HeterocyclicAntineoplastic Combined Chemotherapy ProtocolsSulfonamides

Stichwörter der Autor:innen

adolescent and young adultsinfectionleukemiapediatricvenetoclax

Substanzen

Bridged Bicyclo Compounds, HeterocyclicvenetoclaxSulfonamides

Autor:innen und Institutionen

  • Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, San Francisco, CA, USA.

ORCID-Profile: Amanda E Marinoff, Anurag K Agrawal, Benjamin S Braun, Kieuhoa T Vo, Elliot Stieglitz

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • Alex's Lemonade Stand Foundation for Childhood Cancer

Zitieren

APA

Marinoff, A. E., Aaronson, K., Agrawal, A. K., Braun, B. S., Golden, C., Huang, B. J., Michlitsch, J., Southworth, E., Thrall, A., Vo, K. T., & Stieglitz, E. (2023). Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30335

Vancouver

Marinoff AE, Aaronson K, Agrawal AK, Braun BS, Golden C, Huang BJ, et al. Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30335

BibTeX
@article{Marinoff2023,
  author = {Marinoff, Amanda E and Aaronson, Kathryn and Agrawal, Anurag K and Braun, Benjamin S and Golden, Carla and Huang, Benjamin J and Michlitsch, Jennifer and Southworth, Erica and Thrall, Allyson and Vo, Kieuhoa T and Stieglitz, Elliot},
  title = {Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30335}
}
Kostenlos starten →